TransEnterix, Inc. (NYSE MKT:TRXC) Q3 2018 Earnings Conference Call - Final Transcript
Nov 08, 2018 • 04:30 pm ET
for 2019 because we've not done that in the past as far as geography. But suffice to say, we've got a lot of activity in all the areas that we're working in; US, EMEA, and Asia-Pacific. So I appreciate the question, Drew.
And just one more, if I may, and I'll hop back in queue. But you touched on MST and some of the applications that are coming over the next four to six quarters. I know it's early, but can you just kind of give us a sense of maybe how Senhance could evolve over time with incorporating MST technology beyond these initial applications?
I mean a few of the things that we've talked about publicly in addition to what we talked about on the call here that we just highlighted, these are things that we've heard consistently from surgeons that feels like they are not as capable as they want to be in laparoscopic surgery or they could be much more efficient. One thing we have approval for inguinal hernia and when surgeons go in to repair a hernia, they often put mesh in. They need to understand the size of the defect and either they eyeball it from experience or they'll drop a flexible tape measure into the abdomen and they'll try to stretch it out and measure and then they'll try to replicate those measurements and cut their mesh to the appropriate size. With this technology in the future, we're going to be able to drop icons in and digitally measure right on the spot. This is something that the technology exists outside the operating room. Certainly we see that on our smartphones and some of the navigation in vehicles. We want to bring that to the OR. This MST technology will enable that.
And that's one of those real-world examples that when people need precise measurements quickly interoperatively, you don't have a good way to do that now. And that's just an example, to specifically answer your question, of a few things even beyond what we talked about in the call. So, we're excited about it. But most importantly, the surgeons that we're previewing this with are very excited about it. So they like the near-term additions we're making to the portfolio, but they really like to see that we're being active in the M&A space. But I'd also say that they've commented that they think it's fairly impressive that we announced getting going with this deal into Q3 and have already closed it into Q3. Sometimes hospitals or surgeons worry that companies talk about doing deals that don't actually get them executed and I think we're showing a pretty good core competence with our SOFAR acquisition of Senhance, with MST, that we're very open to look at M&A if it makes sense and we're going to get it acquired. So thanks for the question, Drew.
Jeffrey Cohen, Ladenburg Thalmann.
Just a few issues I wanted to touch upon. So, you had mentioned early in